It has been known for many years that a significant number of deaths result from life-threatening ventricular arrhythmias, most of which occur suddenly in individuals with serious heart disease (1, 2) . Indeed, in patients with chronic congestive heart failure, over half of the deaths are sudden and attributable to ventricular fibrillation. In the United States alone, no less than 300,000 individuals succumb to sudden cardiac death annually, and the prevention of such deaths continues to be an important therapeutic challenge. Arrhythmic deaths occur in a wide range of conditions, including in the setting of heart failure, in patients surviving myocardial infarction, in patients with intrinsic myocardial disease, and in patients with genetically-determined abnormalities of ventricular repolarization.
Not surprisingly, the earliest approach in the preventive arena was in the development and use of antiarrhythmic agents that had the potential for arrhythmia suppression-not only the suppression of ambient arrhythmias but also those produced by programmed electrical stimulation in the clinical electrophysiologic laboratory (3) . Neither technique has survived because controlled trial data subsequently revealed no relationship between suppression of arrhythmias and mortality. The data from controlled trials indicate that the classical antiarrhythmic drugs, such as quinidine, procainamide, disopyramide, and lidocaine and its oral congeners, rather than reducing mortality, actually had the propensity to increase it. This was scientifically disturbing.
These results did, however, pave the way for the exploration of compounds that, unlike conventional antiarrhythmic agents, were not sodium-channel blockers as typified by ,3-adrenergic blocking drugs, sotalol, and amiodarone. A number of large placebo-controlled clinical trials in patients sustaining myocardial infarction and those in heart failure confirmed the potential of f-blockers to reduce total mortality as well as sudden cardiac death, despite a modest effect on arrhythmia suppression (4-7).
The mortality benefit with these agents correlated well with the magnitude of the reduction of heart rate and was evident in a wide spectrum of disorders (8) .The data have been strikingly consistent in the case of the survivors of acute myocardial infarction (2, 4, 8) as well as in patients with cardiac failure with and without ischemic heart disease. In the case of postinfarct patients, total mortality decreased between 25% and 40%, at least 40 % of which was a reduction in sudden cardiac death (8) .
Three decisive double-blind, placebo-controlled trials showed a highly significant and consistent effect on total mortality and on sudden death in patients with cardiac failure (5-7). The most significant features of these three trials (involving metoprolol, bisoprolol, and carvedilol) are similar: all were large trials, most patients enrolled were in heart failure that was predominately of an ischemic origin, and meticulous attention was paid to drug dosage. It so transpired that the 5-blocking potencies of the test agents were also essentially similar and the data on heart rate reduction comparable. It is therefore noteworthy that the total mortality for each of the three trials was approximately 35%, and the rate of sudden death was about 44% for metoprolol, bisoprolol, and carvedilol.
Of particular importance have also been the outcomes of the various placebo-controlled trials with angiotensin-converting enzyme (ACE) inhibitors in heart failure and in patients with impaired ventricular function following myocardial infarction (8) . Here again, as in the case of 3-blockers, ACE inhibitors have been found to consistently and significantly reduce total mortality but with a lesser effect on the incidence of sudden death, reflecting a differing mode of action from that of ,8-blockers (8, 9) .
Moreover, for many decades data have indicated that aspirin reduces sudden death as well as total mortality in various subsets of patients; thus, together with n-blockers, ACE inhibitors and angiotensin-receptor (AR) blockers, aspirin has become an integral component of the overall regimens that are effective in significantly reducing sudden death and total mortality in patients with cardiovascular disease. This is particularly compelling in the case of patients with ischemic heart disease.
To this list one must now add the members of the class of drugs that lower serum lipids, especially the statins (10) (11) (12) . These agents were developed to modulate various components of serum cholesterol to lower serum low-density lipoproteins (LDL) while elevating the high-density lipoproteins (HDL). There is now evidence that as a class statins do prevent the development of atherosclerosis and may induce its regression when present (10) (11) (12) .
The important observation in recent years has been that these drugs have the potential to reduce mortality within a relatively short time after their initial administration in patients with coronary artery disease (10) . Whether this early beneficial effect is mediated by coronary atherosclerotic plaque stabilization or by other mechanisms such as an anti-inflammatory action (11) remains unclear, but the evidence for mortality reduction under their action is compelling and the case for the routine use of this class of drugs in patients with coronary disease is undeniably strong. On the other hand, it is inevitable that the increasing proliferation of cardiovascular drugs that are likely to be used to reduce mortality and morbidity may, in some instances, lead to complex drug interactions.
In the current issue of the Journal of Cardiovascular Pharmacology and Therapeutics, Miltiadous, Mikhalilidis, and Elisaf (13) have drawn attention to the acid-base electrolyte abnormalities in patients receiving cardiovascular drugs. The review is timely. It focuses on the use of oral diuretics; both potassiumlosing as well as potassium-sparing, with an emphasis on the consequences of hyponatremia, hypokalemia, hyperkalemia, and hypomagnesemia, and their treatment and prevention.
In particular, the authors emphasize the significance of drug-induced hyperkalemia in the context of potassium homeostasis in patients on potassium-sparing diuretics such as amiloride, triamterene, and spironolactone. The authors stress that in the presence of preexisting renal insufficiency and diabetes mellitus, serum potassium levels can rise to dangerously high, life-threatening levels of 9.4 to 11 mEq/L within relatively short periods of time when these drugs are combined with an ACE inhibitor (14) .
The authors also cite the example in which significant hyerkalemia developed in a hemodialysis patient taking 300 mg/day of spironolactone, suggesting that aldosterone can also affect the cellular handling of potassium or its gastrointestinal excretion (15) . On the other hand, it should be mentioned that a combination formulation of amiloride/hydrochlorothiazide was developed as an alternative to oral potassium with the sole purpose of preventing hypokalemia induced by potassium-losing diuretics.
In recent years, there have been two significant developments relative to the treatment of heart failure. The first is the use ofACE inhibitors and AR blockers, which became routine practice when it was found that this form of therapy not only alleviates symptoms but also prolongs survival. The second is the demonstration in a double-blind, placebo-controlled trial that low-dose spironolactone in patients with heart failure reduced total mortality compared with placebo (16) .The 1663 patients who participated had severe heart failure and low left ventricular ejection fraction (< 35%): 822 patients were randomly assigned to 25 mg/day of spironolactone and 841 were assigned to placebo. During a follow-up period of 24 months, there were 386 deaths on placebo (46%) and 284 in the spironolactone (35%; P < .001). The authors attributed the 30% reduction in the risk of death from both progressive heart failure, as well as sudden death from cardiac causes, to the administration of lowdose spironolactone. This is clearly a landmark trial, which does establish that the use of low-dose spironolactone in severe heart failure can be a double-edged sword. On the one hand, if diuretics and an ACE inhibitor or an AR blocker are given concomitantly with spironolactone without renal function being regularly monitored, potentially harmful levels of hyperkalemia may expose the patient to life-threatening arrhythmias (14) . On the other hand, the placebo-controlled trial data indicate that overall survival of patients with severe heart failure may be increased and may be additive to that attained by the concomitant use of f-blockers, ACE inhibitors, AR blockers, statins, and aspirin. This cumulative survival advantage is undoubtedly real.
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The data on these expanding and potent regimens that exert a major impact on sudden death and allcause mortality raise the intriguing possibility that in many patients with advanced heart failure, these drug regimens may obviate the need for the routine use of the implantable cardioverter defibrillator. At the very least, the data should engender consideration for the retesting of the device against the full background therapy that impacts sudden death and mortality in patients with advanced cardiac failure.
